AccessPak for HIV PEP Basic and Alcohol/Food Interactions
There is 1 alcohol/food/lifestyle interaction with AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil).
Tenofovir Food
Minor Food Interaction
Food enhances the oral absorption and bioavailability of tenofovir, the active entity of tenofovir disoproxil fumarate. According to the product labeling, administration of the drug following a high-fat meal increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of tenofovir by approximately 14% and 40%, respectively, compared to administration in the fasting state. However, administration with a light meal did not significantly affect the pharmacokinetics of tenofovir compared to administration in the fasting state. Food delays the time to reach tenofovir Cmax by approximately 1 hour. Tenofovir disoproxil fumarate may be administered without regard to meals.
References (1)
- (2001) "Product Information. Viread (tenofovir)." Gilead Sciences
Switch to consumer interaction data
AccessPak for HIV PEP Basic drug interactions
There are 245 drug interactions with AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil).
AccessPak for HIV PEP Basic disease interactions
There are 7 disease interactions with AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil) which include:
- hepatitis B
- hepatotoxicity
- hemodialysis
- renal dysfunction
- bone toxicity
- liver disease
- renal dysfunction
More about AccessPak for HIV PEP Basic (emtricitabine / tenofovir disoproxil)
- AccessPak for HIV PEP Basic consumer information
- Check interactions
- Compare alternatives
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antiviral combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.